BioNTech sees scope for further capacity expansion: CFO
- Wall Street ends volatile week sharply higher
- Disney (DIS) Dips As Streaming Business Shows Signs of Slowing Down, Analysts 'Very Bullish' on LT Opportunity
- Airbnb (ABNB) Bookings Up 52% to Help Sales Beat, Seen as a 'Blow Out Quarter' as More Upside is Left
- DoorDash (DASH) Reports Bigger Loss and a Sales Beat, Shares Soars on Strong Guidance and Two Upgrades to 'Buy'
- Coinbase (COIN) To Add Dogecoin Trading in the Next Few Weeks
FILE PHOTO: Sierk Poetting, CFO of German biotech firm BioNTech, is interviewed by journalists in Marburg, Germany September 17, 2020. REUTERS/Fabian Bimmer
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
BERLIN (Reuters) - German COVID-19 vaccine maker BioNtech is open to further capacity expansion and the construction of new production facilities depending on demand, Chief Financial Officer Sierk Poetting said.
"There is still room for improvement. But that will ultimately also depend on demand," Poetting said in an interview with the Handelsblatt newspaper published on Wednesday.
Poetting said if premises were available, BioNtech could build up additional production capacity in six months, adding that discussions were ongoing.
"We have a lot of inquiries," the CFO said.
The Mainz-based biotech company and its U.S. partner Pfizer plan to produce 2.5 billion COVID-19 doses this year, of which 1.4 billion were already sold. The companies aim to raise production to three billion shots in 2022.
BioNTech in February launched production at its new site in the city of Marburg, which it purchased from Novartis last year, raising its annual capacity by around 1 billion doses.
(Reporting by Riham Alkousaa; editing by Jason Neely)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delayed 2nd Pfizer/BioNTech shot boosts antibodies in elderly; COVID-19 obesity risk higher for men
- Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
- CDC advisory committee votes Pfizer (PFE) BioNTech SE (BNTX) Covid vaccine should be recommended for age 12-15
Create E-mail Alert Related CategoriesGeneral News, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!